You are here

Clinical update

iCMLf Forum 2022: The Next Big Challenges in CML? Webstreams

sandy craine's picture
Submitted by sandy craine on Sat, 04/03/2023 - 3:52pm

Webstreams of the presentations and discussions from the iCMLf Forum 2022 that took place on December 9th 2022 in News Orleans (USA), are now available to view. At this forum, our speakers and panellists of renowned experts in the field took a look at future directions of CML. What are the next big challenges in CML? What are the most promising new approaches? What research questions need to be answered to help us to move closer to a cure for CML?

Topics include:

iCMLf Conversation- Treatment of CML patients after failure of 2 TKIs

sandy craine's picture
Submitted by sandy craine on Sat, 23/07/2022 - 1:49pm

Hear about current practices for third-line management of CML and get first-hand expert knowledge from:

Professor Andreas Hochhaus
Head of the Department of Hematology and Medical Oncology,
Jena University Hospital, Germany

Date: August 24th 2022 at 2 pm Central European Summer Time (CEST)

How can I dial into the webinar?

Join this meeting from your computer, tablet or smartphone via the link:
https://us02web.zoom.us/j/87340646441

iCMLf- Highlights of EHA 2022

sandy craine's picture
Submitted by sandy craine on Tue, 28/06/2022 - 11:15am

CML Highlights of EHA 2022 – Biological and clinical overview

Join our two experts as they discuss key aspects of the CML presentations:

Clinical overview: Professor Timothy Hughes,
Precision Medicine Theme Leader at SAHMRI, Beat Cancer Professor at the University of Adelaide and Consultant Haematologist, Royal Adelaide Hospital (Australia)

Biological overview: Professor Dominik Wolf, Head, Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck (Austria)

TFR in chronic myeloid leukemia: Lights and shadows. In several studies, NK cell numbers or functional subsets of NK cells were shown to be higher in patients who maintain TFR

sandy craine's picture
Submitted by sandy craine on Sat, 26/03/2022 - 10:18am

'Among challenges of TFR, it is also included the better identification of patients who have a high probability of relapsing compared with those who experience a successful TFR. Some of the most promising data involve the field of immunology, especially T-cell cytotoxicity and NK cell effects. In several studies, NK cell numbers or functional subsets of NK cells were shown to be higher in patients who maintain TFR than in those who lose molecular response during TKI discontinuation.'

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission

sandy craine's picture
Submitted by sandy craine on Tue, 01/03/2022 - 2:29pm

This review will present the current studies that are helping to increase our understanding of the biological factors (clinical and non-clinical, cellular, and molecular) that may determine TKI discontinuation success

https://link.springer.com/article/10.1007/s11912-022-01228-w

Pages